Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 9, 2013

MEDNAX, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Florida

 

001-12111

 

26-3667538

(State or Other Jurisdiction of

Incorporation)

 

(Commission File

Number)

  (IRS Employer Identification No.)

1301 Concord Terrace

                            Sunrise, Florida 33323                            

(Address of principal executive office) (zip code)

 

Registrant’s telephone number, including area code (954) 384-0175

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 9, 2013, MEDNAX, Inc., a Florida corporation (the “Company”), held its 2013 Annual Shareholders’ Meeting (the “Annual Meeting”). Of the 50,168,072 shares of common stock outstanding and entitled to vote, 45,396,955 shares were represented, constituting a quorum. The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting are as follows:

Proposal 1: All of the Board’s nominees for Director were elected to serve until the Company’s 2014 Annual Shareholders’ Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below:

 

Name

   For      Withheld      Broker
Non-Vote
 

Cesar L. Alvarez

     39,055,857         4,872,149         1,468,949   

Waldemar A. Carlo, M.D.

     39,885,897         4,042,109         1,468,949   

Michael B. Fernandez

     39,866,633         4,061,373         1,468,949   

Roger K. Freeman, M.D.

     39,537,681         4,390,325         1,468,949   

Paul G. Gabos

     43,778,169         149,837         1,468,949   

Pascal J. Goldschmidt, M.D.

     43,777,795         150,211         1,468,949   

Manuel Kadre

     40,886,557         3,041,449         1,468,949   

Roger J. Medel, M.D.

     43,058,539         869,467         1,468,949   

Donna E. Shalala, Ph.D.

     43,777,757         150,249         1,468,949   

Enrique J. Sosa, Ph.D.

     43,757,614         170,392         1,468,949   

Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered certified public accounting firm for the 2013 fiscal year was ratified by the shareholders, by the votes set forth in the table below:

 

For

 

Against

 

Abstained

 

Broker

Non-Vote

44,382,160

  1,009,206   5,589   0

Proposal 3: The shareholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, by the votes set forth in the table below:

 

For

 

Against

 

Abstained

 

Broker

Non-Vote

28,160,891

  15,752,697   14,418   1,468,949


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MEDNAX, INC.
Date: May 10, 2013     By:   /s/ Vivian Lopez-Blanco
      Vivian Lopez-Blanco
      Chief Financial Officer